ManagementManagementManagementManagement
  • About Lixte
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
  • About Lixte
    • Management
    • Board of Directors
    • Forward-Looking Statements
  • Product Development
  • Publications
  • Investor Information
    • Investor Alerts
menu toggle
Close
Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Feb 09, 2018 9:45am EST

LB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors

Apr 17, 2017 9:45am EDT

Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model

Mar 09, 2017 10:30am EST

Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting

Jan 04, 2017 11:45am EST

First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research

Jun 07, 2016 9:35am EDT

Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors

Feb 03, 2016 10:00am EST

Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression

Jan 25, 2016 10:30am EST

Lixte Completes Private Placement of Convertible Preferred Stock

Dec 30, 2015 9:35am EST

Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University

Nov 06, 2015 12:30pm EST

Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity

Sep 17, 2015 1:00pm EDT

Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact

Lixte Biotechnology Holdings, Inc.
248 Route 25A No. 2 East Setauket, NY 11733
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
Fax: (631) 982-5050
info@lixte.com
Lixte Biotechnology Holdings, Inc. is publicly traded as LIXT.

About LIXTE

  • About Lixte
  • Management
  • Board of Directors
  • Forward-Looking Statements

Development

  • Product Development

Publications

  • Publications

Investor Information

  • Investor Information
  • Email Alerts
Back to top
© 2021 Lixte Biotechnology Holdings, Inc. (Lixte). All Rights Reserved. Site by Third Eye Industries
    Close